Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Silexion Therapeutics ( (SLXN) ) is now available.
On July 14, 2025, Silexion Therapeutics reconvened its annual general meeting after an adjournment due to the absence of a quorum. During the meeting, shareholders approved several proposals, including the election of board members, the ratification of auditors, a reverse share split, and an increase in shares for the equity incentive plan. These decisions are expected to influence the company’s governance and financial strategies moving forward.
The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp operates in the biotechnology industry, focusing on the development of therapeutic solutions. The company is involved in creating innovative medical treatments and is positioned to impact the healthcare market significantly.
Average Trading Volume: 1,858,844
Technical Sentiment Signal: Sell
Current Market Cap: $6.87M
For a thorough assessment of SLXN stock, go to TipRanks’ Stock Analysis page.